Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 6/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | MTTP | P55157 | 3/20 | 0.34 |
| ▸ | APOB | P04114 | 2/20 | 0.34 |
| ▸ | SMO | Q99835 | 3/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3044444 | 0.87 | SLC2A1 (0.45) | SLC2A1PRMT5HTR5AMTTPAPOB | |
| SCHEMBL3040298 | 0.82 | BDKRB1 (0.31) | ALOX5APFEN1 | |
| SCHEMBL3047057 | 0.81 | PRMT5 (0.39) | PRMT5OPRM1OPRD1OPRK1ALOX5AP | |
| Hydrochloric Acid SCHEMBL3046989 | 0.81 | PRMT5 (0.38) | PRMT5OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL3044195 | 0.81 | PRMT5 (0.39) | PRMT5OPRM1OPRD1OPRK1ALOX5AP | |
| SCHEMBL13137013 | 0.78 | ALOX5AP (0.36) | SLC2A1OPRM1OPRD1OPRK1ALOX5AP | |
| Hydrochloric Acid SCHEMBL3050595 | 0.78 | PRMT5 (0.39) | PRMT5OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL3044289 | 0.77 | PDCD1 (0.34) | OPRM1 | |
| SCHEMBL13137225 | 0.76 | ALOX5AP (0.38) | PRMT5OPRM1OPRD1OPRK1ALOX5AP | |
| Hydrochloric Acid SCHEMBL3042171 | 0.76 | PRMT5 (0.41) | PRMT5OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | SLC2A1 4262/4885PRMT5 2811/4885OPRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.